Identifying prediabetes using fasting insulin levels

Endocrine Practice

Volumn 16, Issue 1, 2010, Pages 47-52

  Johnson, Jennal L ^a   Duick, Daniel S ^a   Chui, Michelle A ^b   Aldasouqi, Saleh A ^c  

^a Endocrinology Associates   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c St Francis Medical Center Cape Girardeau   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGING; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDIABETIC STATE; RETROSPECTIVE STUDIES;

EID: 77649114516     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09031.OR     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. http://apps.nccd.cdc.gov/DDTSTRS/FactSheet.aspx. Accessed January 22, 2009.
2. National Institute of Diabetes and Digestive Kidney Diseases. National Diabetes Information Clearinghouse Web site. www.diabetes.niddk.nih. gov/intro/index.htm. Accessed January 22, 2009.
3. Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity (Silver Spring). 2006;14(Suppl 3):121S-127S.
4. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214.
5. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134.
6. Faeh D, William J, Yerly P, Paccaud F, Bovet P. Diabetes and pre-diabetes are associated with cardiovascular risk factors and carotid/femoral intima-media thickness independently of markers of insulin resistance and adiposity. Cardiovasc Diabetol. 2007;6:32.
7. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24:137-144.
8. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23:171-175.
9. Ferrara CM, Goldberg AP. Limited value of the homeostasis model assessment to predict insulin resistance in older men with impaired glucose tolerance. Diabetes Care. 2001;24:245-249.
10. Yokoyama J, Emoto M, Fujiwara S, et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose. J Clin Endocrinol Metab. 2004:89:1481-1484.
11. Boyko EJ, Jensen CC. Do we know what homeostasis model assessment measures? If not, does it matter? Diabetes Care. 2007:30:2725-2728.
12. Drzewoski J, Czupryniak L. Concordance between fasting and 2-h post-glucose challenge criteria for the diagnosis of diabetes mellitus and glucose intolerance in high risk individuals. Diabet Med. 2001;18:29-31.
13. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
14. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial (erratum in Lancet. 2006;368:1770). Lancet. 2006;368:1096-1105.
15. Immulite 2000 [insulin assay handbook]. Llanberis, United Kingdom: Siemens; 2008.
16. Shrive FM, Stuart H, Quan H, Ghali WA. Dealing with missing data in a multi-question depression scale: A comparison of imputation methods. BMC Med Res Methodol. 2006:6:57.
17. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988:240:1285-1293.
18. Kim SH, Abbasi F, Reaven GM. Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care. 2004;27:1998-2002.
19. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care. 2007;30:228-233.
20. Tripathy D, Carlsson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: Lessons from the Botnia Study. Diabetes. 2000;49:975-980.
21. Lindström J, Tuomilehto J. The diabetes risk score. Diabetes Care. 2003;26:725-731.